Recce Pharmaceuticals' R327G Shows Promise in Phase II ABSSSI Trial
Recce Pharmaceuticals' Phase II trial of R327G for ABSSSI reaches a milestone with 20 of 30 patients dosed, indicating strong progress.
© Copyright 2025. All Rights Reserved by MedPath